PAVmed Inc. (PAVM)

NASDAQ: PAVM · IEX Real-Time Price · USD
0.443
+0.018 (4.24%)
At close: Jun 2, 2023, 4:00 PM
0.460
+0.017 (3.84%)
After-hours: Jun 2, 2023, 7:57 PM EDT
4.24%
Market Cap 46.30M
Revenue (ttm) 634,000
Net Income (ttm) -90.33M
Shares Out 104.53M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,470,564
Open 0.429
Previous Close 0.425
Day's Range 0.425 - 0.480
52-Week Range 0.350 - 2.340
Beta 0.85
Analysts Buy
Price Target 1.50 (+238.68%)
Earnings Date May 16, 2023

About PAVM

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo,... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Apr 28, 2016
Employees 124
Stock Exchange NASDAQ
Ticker Symbol PAVM
Full Company Profile

Financial Performance

In 2022, PAVmed's revenue was $377,000, a decrease of -24.60% compared to the previous year's $500,000. Losses were -$89.26 million, 76.3% more than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for PAVM stock is "Buy." The 12-month stock price forecast is $1.5, which is an increase of 238.68% from the latest price.

Price Target
$1.5
(238.68% upside)
Analyst Consensus: Buy
Stock Forecasts

News

PAVmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot's CancerX Partnership as Founding Member

NEW YORK , June 2, 2023 /PRNewswire/ -- PAVmed Inc.  (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digi...

1 day ago - PRNewsWire

PAVmed Provides Business Update and First Quarter Financial Results

EsoGuard® test volume gains momentum as Lucid expands high-volume testing events PAVmed appoints President for Veris Health and expands commercial footprint Conference call and webcast to be held tomo...

Other symbols: LUCD
2 weeks ago - PRNewsWire

Lucid Diagnostics Provides Business Update and First Quarter Financial Results

EsoGuard® test volume increases 57 percent sequentially and 245 percent year-on-year Conference call and webcast to be held tomorrow, May 16 th at 8:30 AM EST NEW YORK , May 15, 2023 /PRNewswire/ --  ...

Other symbols: LUCD
2 weeks ago - PRNewsWire
}

Lucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference

EsoGuard® continues to demonstrate excellent esophageal precancer and cancer detection performance, including in most prevalent and challenging precancer subgroup—short segment non-dysplastic Barrett'...

Other symbols: LUCD
3 weeks ago - PRNewsWire

PAVmed to Hold a Business Update Conference Call and Webcast on May 17, 2023

NEW YORK, May 5, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnos...

1 month ago - PRNewsWire

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 16, 2023

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , May 5, 2023 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medica...

Other symbols: LUCD
1 month ago - PRNewsWire

PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President

NEW YORK, April 25, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digi...

1 month ago - PRNewsWire

PAVmed Digital Health Subsidiary, Veris Health, to Present Comprehensive Meta-analysis on Impact of Remote Patient Monitoring in Oncology at HIMSS

Company presenting at highly influential HIMSS23 Global Health Conference, today, April 19, 2023 from 11:30 a.m. to 12:30 p.m.

1 month ago - PRNewsWire
}

Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer

Foundational LCD, to be effective May 14, 2023, incorporates key feedback to 2022 draft, including updated guidelines recommending non-endoscopic biomarker testing Lucid positioned to submit EsoGuard ...

Other symbols: LUCD
2 months ago - PRNewsWire

PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results

Conference call and webcast to be held tomorrow, March 15 th at 8:30 AM EST NEW YORK , March 14, 2023 /PRNewswire/ -- PAVmed Inc.  (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified comm...

2 months ago - PRNewsWire

PAVmed to Hold a Business Update Conference Call and Webcast on March 15, 2023

NEW YORK, March 3, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagn...

3 months ago - PRNewsWire

PAVmed Digital Health Subsidiary Veris Health's Veris Cancer Care Platform™ Goes Live

Remote patient monitoring of first cohort of cancer patients using VerisBox™ connected devices and Veris CCP smartphone app initiated Cancer care team utilizing physiologic data and patient reported s...

3 months ago - PRNewsWire

PAVmed and Lucid Diagnostics Provide Strategic Business Update

NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health se...

Other symbols: LUCD
4 months ago - Business Wire
}

PAVmed and Lucid Diagnostics to Provide Strategic Business Update

NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and ...

Other symbols: LUCD
5 months ago - Business Wire

PAVmed Partners with Novosound on Ultrasound Imaging Technology

NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health ...

5 months ago - Business Wire

Ultrasound Sensor Specialist Novosound Inks Deal With Nasdaq-listed PAVmed Inc. to Advance Intravascular Imaging Technology

GLASGOW, Scotland--(BUSINESS WIRE)--Ultrasound sensor specialist Novosound has signed a commercial partnership agreement with PAVmed Inc., the Nasdaq-listed diversified medical technology company, t...

5 months ago - Business Wire

PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform

NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health ...

6 months ago - Business Wire

Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry

NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVm...

Other symbols: LUCD
6 months ago - Business Wire

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

NEW YORK--(BUSINESS WIRE)--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: P...

Other symbols: LUCD
6 months ago - Business Wire

PAVmed Provides Business Update and Third Quarter 2022 Financial Results

NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, an...

Other symbols: LUCD
7 months ago - Business Wire

Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results

NEW YORK--(BUSINESS WIRE)--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVme...

Other symbols: LUCD
7 months ago - Business Wire

PAVmed to Participate in BTIG Digital Health Forum

NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”, the “Company”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and d...

7 months ago - Business Wire

Lucid Diagnostics to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

NEW YORK--(BUSINESS WIRE)-- #CheckYourFoodTube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned su...

Other symbols: LUCD
7 months ago - Business Wire

Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer

NEW YORK--(BUSINESS WIRE)-- #CheckYourFoodTube--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned su...

Other symbols: LUCD
7 months ago - Business Wire

PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2022

NEW YORK--(BUSINESS WIRE)---- $PAVM #1x1meetings--PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical device company today announced that the Company will host a business update ...

7 months ago - Business Wire